Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00131261
Status:
COMPLETED
Last Update Posted:
2015-07-08
First Post:
2005-08-17
Brief Title:
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Sponsor:
Valerio Therapeutics
Organization:
Valerio Therapeutics
Study Overview
Official Title:
A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this open-label non-randomized trial is to assess the safety and effectiveness of PXD101 both alone and in combination with dexamethasone in patients with advanced multiple myeloma PXD101 is a new potent histone deacetylase HDAC inhibitor Various members of this class of drugs have shown activity in preclinical studies and in initial clinical trials of multiple myeloma and lymphoma Furthermore HDAC inhibitors including PXD101 have been shown to sensitize myeloma cells to the killing effect of other chemotherapeutic agents including dexamethasone a well-established agent in relapsing myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None